Compare ARTW & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTW | IOBT |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 12.7M |
| IPO Year | 1996 | 2021 |
| Metric | ARTW | IOBT |
|---|---|---|
| Price | $2.60 | $0.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 40.0K | ★ 186.6M |
| Earning Date | 04-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | 26.77 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $22,975,408.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.69 | $0.03 |
| 52 Week High | $4.69 | $2.79 |
| Indicator | ARTW | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 25.94 |
| Support Level | $2.12 | N/A |
| Resistance Level | $2.96 | $0.22 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 2.90 | 15.92 |
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.